Morgan Stanley Hoth Therapeutics, Inc. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.36 - $9.25 $1,836 - $47,175	-5,100 Reduced 99.8%	10 $0
Q2 2022 Oct 27, 2022	SELL	$0.38 - $1.05 $46 - $129	-123 Reduced 2.35%	5,110 $2,000
Q2 2022 Aug 15, 2022	SELL	$0.38 - $1.05 $46 - $129	-123 Reduced 2.35%	5,110 $2,000
Q1 2022 Oct 27, 2022	BUY	$0.52 - $1.3 $63 - $159	123 Added 2.41%	5,233 $4,000
Q1 2022 May 13, 2022	BUY	$0.52 - $1.3 $2,663 - $6,658	5,122 Added 4614.41%	5,233 $4,000
Q4 2021 Feb 14, 2022	BUY	$0.66 - $1.18 $0 - $1	1 Added 0.91%	111 $0
Q3 2021 Nov 15, 2021	BUY	$1.15 - $1.62 $126 - $178	110 New	110 $0

Ticker HOTH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 1,288,470
Market Cap $1.08M
Description
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.